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such as escitalopram and desvenlafax-
ine. Moreover, fewer patients are then
needed to identify antidepressant effect
in controlled trials, which has impor-
tant ethical implications (fewer pa-
tients need to receive placebo).
In my opinion, we need to aim at
establishing “dose-remission” rather
than dose-response relationship in fu-
ture trials of antidepressants. The
HAM-D-6 contains the core symp-
toms of depression by which to define
the event of remission.
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Many randomized trials have shown
that when depressed patients receive
no active treatment, e.g. they are
administered pill placebo, a large part
of them improve anyway. This im-
provement can be partly explained by
natural remission or by the patients’
expectations that a treatment will have
an effect on their problems (even when
they receive pill placebo). The corollary
is that many patients remit even when
undergoing exotic therapies, such as
Argentian tango, swimming with dol-
phins or horticulture (1-3).
This phenomenon makes it difficult
to examine the additional effects of spe-
cific treatments. This is not only true for
pharmacotherapy, but also for psycho-
therapies for depression. In a recent
meta-analysis, we found that 62% of
patients meeting criteria for major
depression at baseline did no longer
meet these criteria after treatment (4).
But among the patients receiving only
care-as-usual, 48% also no longer met
criteria for major depressive disorder.
So, therapists may think that more than
60% of patients get better because of
the psychotherapy, while in fact the
additional benefit of psychotherapy
over usual care is only 14%. Khan and
Brown (5) indicate that comparable
outcomes take place for pharmacother-
apy, with symptom reduction of about
40% with antidepressants and 30%
with placebo. That is in line with Kline’s
conclusion in 1964 that “in the treat-
ment of depression, one always has an
ally in the fact thatmost depressions ter-
minate in spontaneous remissions” (6).
Given this large proportion of patients
who remit spontaneously, patients as
well as therapists can easily be led into
the idea that their treatment is highly
successful, while in fact the effects of
this treatment may be only moderate.
This may also explain why the exotic
treatments mentioned earlier are be-
lieved by some to be effective, while
most clinicians would consider the
specific effects of such treatments as
not very credible. “But we see that
patients get better” is a phrase that
supporters of such therapies often use.
Due to the discrepancy between the
relatively high rate of spontaneous
remission and the low additional value
of specific (pharmacological and psy-
chological) treatments, several impor-
tant issues arise. One question is wheth-
er these treatments do in fact have any
effects. Of course, randomized trials
show that pharmacotherapy and psy-
chotherapy are effective for treating
depression, with small effect sizes of
0.30 for antidepressants (5) and 0.25 for
psychotherapies (7). But we also know
that these effects are much higher when
risk of bias is not taken into account. In
fact, only the highest quality studies
show such small effects, and only after
publication bias has been adjusted for.
But suppose there is still a bias lin-
gering in these trials. For example,
since patients getting a placebo know
that they are not receiving active
medication because they experience
no side effects, this breaks the blinding
and serves to lower their expectations.
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Ameta-analysis of trials with active pla-
cebos pointed exactly in this direction
(8). Or investigators’ choices may influ-
ence the trial outcomes in ways that are
just not known, for example by selecting
those patients who are expected to
respond well to treatment but not to
placebo (9). The effects of the active
treatments are so small that only slight
tweaking because of some bias may fur-
ther them, and make them clinically
irrelevant. The same is true for psycho-
therapies. Their effects compared with
pill placebo are very small and, because
patients cannot be blinded at all,
expectations may have a considerable
effect on the outcomes. Only a small
adjustment because of an unknown risk
of bias could move these effects into
clinical irrelevance aswell.
The other implication is that research
should focus much more on how spon-
taneous remission takes place. Now
most of the research is focused on the
brain changes and the psychological
mechanisms involved in the action of
biological and psychological therapies.
However, the process through which
spontaneous remission occurs is at least
as important as themechanisms through
which these specific treatments work,
particularly since their additional effec-
tiveness is not as high as has been
thought for a long time.
Hence, a clinical issue in need of
much more investigation is by what
mechanisms spontaneous remission
can be optimized. For example, it can be
assumed that when expectations of out-
come are higher, spontaneous remission
is more likely to occur. If we understood
this process better, we could also find
ways to optimize expectations and thus
increase remission rates. That would
eventually reduce the relative contri-
bution of current treatments towards
remission, though they still may lead to
better outcomes for patients.
Khan and Brown conclude that the
effects of antidepressants are modest,
and other research shows that the same
holds for psychological treatments for
depression. We argue that the high rate
of spontaneous remission introduces
considerable confusion about the effec-
tiveness of treatments. In order to im-
prove outcomes for patients we have to
face facts, and focus much more on the
process of natural recovery instead of
on the limited contributions of specific
treatments.
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